Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Accepts Extended Duration sNDA for Miudella Hormone-Free IUD

14 September 2026 · By · Wire by Fusion42

Published

14 September 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at patientcareonline.com →

◆ Verified

Fusion42 · 14 September 2026 · Fusion42 review

The FDA has accepted a Supplemental New Drug Application (sNDA) for extending the duration of Miudella, a hormone-free intrauterine device (IUD), signaling regulatory progress towards potentially longer-use contraceptive options.

This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

You gain a regulatory green light that could broaden your market for hormone-free IUDs by extending their approved use. Adjust your product timelines and sales strategies to capitalise on this extended duration approval pathway.

◆ Coverage

2 sources · 14 Sep 2026

◆ Related on Wire

◆ Topics

MedtechFDAcontraceptivemedtech-regulationIUDhormone-free